Hayes F A, Green A A
J Clin Oncol. 1984 Nov;2(11):1229-34. doi: 10.1200/JCO.1984.2.11.1229.
Malignant melanoma is uncommon in patients less than 20 years of age, and little is known about the response to chemotherapy in this age group. We report here a series of 18 children, of whom ten with metastatic disease were treated with cyclophosphamide, vincristine, and dactinomycin. Only two of nine evaluable patients failed to show an objective response to therapy. Five of ten patients treated are alive and free of tumor 12 to 80 months from the start of chemotherapy. Three have been in remission for more than five years. Results suggest that melanoma in this age group may be more responsive to chemotherapy than melanoma in adult patients and that a trial of this therapy in a larger number of children with evaluable disease is warranted.
恶性黑色素瘤在20岁以下的患者中并不常见,对于该年龄组患者对化疗的反应了解甚少。我们在此报告18例儿童患者,其中10例转移性疾病患者接受了环磷酰胺、长春新碱和放线菌素治疗。9例可评估患者中只有2例对治疗未表现出客观反应。10例接受治疗的患者中有5例在化疗开始后12至80个月存活且无肿瘤。3例已缓解超过5年。结果表明,该年龄组的黑色素瘤可能比成年患者的黑色素瘤对化疗更敏感,因此有必要对更多可评估疾病的儿童进行这种治疗试验。